Bilirubin is considered to be one of the most potent endogenous antioxidants in humans. Its serum concentrations are predominantly affected by the activity of hepatic bilirubin UDP-glucuronosyl transferase (UGT1A1). Our objective was to analyze the potential bilirubin-modulating effects of natural polyphenols from milk thistle (Silybum marianum), a hepatoprotective herb. Human hepatoblastoma HepG2 cells were exposed to major polyphenolic compounds isolated from milk thistle. Based on in vitro studies, 2,3-dehydrosilybins A and B were selected as the most efficient compounds and applied either intraperitoneally or orally for seven days to C57BL/6 mice. After, UGT1A1 mRNA expression, serum, intrahepatic bilirubin concentrations, and lipoperoxidation in the liver tissue were analyzed. All natural polyphenols used increased intracellular concentration of bilirubin in HepG2 cells to a similar extent as atazanavir, a known bilirubinemia-enhancing agent. Intraperitoneal application of 2,3-dehydrosilybins A and B (the most efficient flavonoids from in vitro studies) to mice (50 mg/kg) led to a significant downregulation of UGT1A1 mRNA expression (46 ± 3% of controls, p < 0.005) in the liver and also to a significant increase of the intracellular bilirubin concentration (0.98 ± 0.03vs.1.21 ± 0.02 nmol/mg, p < 0.05). Simultaneously, a significant decrease of lipoperoxidation (61 ± 2% of controls, p < 0.005) was detected in the liver tissue of treated animals, and similar results were also observed after oral treatment. Importantly, both application routes also led to a significant elevation of serum bilirubin concentrations (125 ± 3% and 160 ± 22% of the controls after intraperitoneal and oral administration, respectively, p < 0.005 in both cases). In conclusion, polyphenolic compounds contained in silymarin, in particular 2,3-dehydrosilybins A and B, affect hepatic and serum bilirubin concentrations, as well as lipoperoxidation in the liver. This phenomenon might contribute to the hepatoprotective effects of silymarin.

4th Department of Internal Medicine 1st Faculty of Medicine Charles University Kateřinská 32 Praha 2 12000 Czech Republic

Institute of Medical Biochemistry and Laboratory Diagnostics 1st Faculty of Medicine Charles University Kateřinská 32 Praha 2 12000 Czech Republic

Laboratory of Biotransformation Institute of Microbiology of the Czech Academy of Sciences Vídeňská 1082 Praha 4 14000 Czech Republic

Zobrazit více v PubMed

Stocker R., Yamamoto Y., McDonagh A. F., Glazer A. N., Ames B. N. Bilirubin is an antioxidant of possible physiological importance. Science. 1987;235(4792):1043–1046. doi: 10.1126/science.3029864. PubMed DOI

Gazzin S., Vitek L., Watchko J., Shapiro S. M., Tiribelli C. A novel perspective on the biology of bilirubin in health and disease. Trends in Molecular Medicine. 2016;22(9):758–768. doi: 10.1016/j.molmed.2016.07.004. PubMed DOI

Jangi S., Otterbein L., Robson S. The molecular basis for the immunomodulatory activities of unconjugated bilirubin. The International Journal of Biochemistry & Cell Biology. 2013;45(12):2843–2851. doi: 10.1016/j.biocel.2013.09.014. PubMed DOI

Ollinger R., Kogler P., Troppmair J., et al. Bilirubin inhibits tumor cell growth via activation of ERK. Cell Cycle. 2007;6(24):3078–3085. doi: 10.4161/cc.6.24.5022. PubMed DOI

Molzer C., Huber H., Steyrer A., et al. Interaction between TNFone and tetrapyrroles may account for their anti-genotoxic effects — a novel mechanism for DNA-protection. Journal of Porphyrins and Phthalocyanines. 2013;17(12):1157–1166. doi: 10.1142/S1088424613500995. DOI

Bulmer A. C., Ried K., Blanchfield J. T., Wagner K. H. The anti-mutagenic properties of bile pigments. Mutation Research. 2008;658(1-2):28–41. doi: 10.1016/j.mrrev.2007.05.001. PubMed DOI

Zelenka J., Dvorak A., Alan L., Zadinova M., Haluzik M., Vitek L. Hyperbilirubinemia protects against aging-associated inflammation and metabolic deterioration. Oxidative Medicine and Cellular Longevity. 2016;2016:10. doi: 10.1155/2016/6190609.6190609 PubMed DOI PMC

Stec D. E., John K., Trabbic C. J., et al. Bilirubin binding to PPARα inhibits lipid accumulation. PLoS One. 2016;11(4, article e0153427) doi: 10.1371/journal.pone.0153427. PubMed DOI PMC

Wagner K. H., Wallner M., Molzer C., et al. Looking to the horizon: the role of bilirubin in the development and prevention of age-related chronic diseases. Clinical Science. 2015;129(1):1–25. doi: 10.1042/CS20140566. PubMed DOI

Vitek L. Bilirubin and atherosclerotic diseases. Physiological Research. 2017;66(Supplement 1):S11–S20. PubMed

Lin J. P., Vitek L., Schwertner H. A. Serum bilirubin and genes controlling bilirubin concentrations as biomarkers for cardiovascular disease. Clinical Chemistry. 2010;56(10):1535–1543. doi: 10.1373/clinchem.2010.151043. PubMed DOI

McCarty M. F. “Iatrogenic Gilbert syndrome” - a strategy for reducing vascular and cancer risk by increasing plasma unconjugated bilirubin. Medical Hypotheses. 2007;69(5):974–994. doi: 10.1016/j.mehy.2006.12.069. PubMed DOI

Estrada V., Monge S., Gomez-Garre D., et al. Comparison of oxidative stress markers in HIV-infected patients on efavirenz or atazanavir/ritonavir-based therapy. Journal of the International AIDS Society. 2014;17(4, article 19544) Supplement 3 doi: 10.7448/ias.17.4.19544. PubMed DOI PMC

Milian J., Goldfine A. B., Zuflacht J. P., Parmer C., Beckman J. A. Atazanavir improves cardiometabolic measures but not vascular function in patients with long-standing type 1 diabetes mellitus. Acta Diabetologica. 2015;52(4):709–715. doi: 10.1007/s00592-014-0708-6. PubMed DOI PMC

Dekker D., Dorresteijn M. J., Pijnenburg M., et al. The bilirubin-increasing drug atazanavir improves endothelial function in patients with type 2 diabetes mellitus. Arteriosclerosis, Thrombosis, and Vascular Biology. 2011;31(2):458–463. doi: 10.1161/ATVBAHA.110.211789. PubMed DOI

Mohamed M. E., Frye R. F. Effects of herbal supplements on drug glucuronidation. Review of clinical, animal, and in vitro studies. Planta Medica. 2011;77(4):311–321. doi: 10.1055/s-0030-1250457. PubMed DOI

Mohamed M. F., Tseng T., Frye R. F. Inhibitory effects of commonly used herbal extracts on UGT1A1 enzyme activity. Xenobiotica. 2010;40(10):663–669. doi: 10.3109/00498254.2010.505669. PubMed DOI

D'Andrea V., Perez L. M., Sanchez Pozzi E. J. Inhibition of rat liver UDP-glucuronosyltransferase by silymarin and the metabolite silibinin-glucuronide. Life Sciences. 2005;77(6):683–692. doi: 10.1016/j.lfs.2005.01.011. PubMed DOI

Flaig T. W., Gustafson D. L., Su L. J., et al. A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Investigational New Drugs. 2007;25(2):139–146. doi: 10.1007/s10637-006-9019-2. PubMed DOI

Rutter K., Scherzer T. M., Beinhardt S., et al. Intravenous silibinin as ‘rescue treatment’ for on-treatment non-responders to pegylated interferon/ribavirin combination therapy. Antiviral Therapy. 2011;16(8):1327–1333. doi: 10.3851/IMP1942. PubMed DOI

Marino Z., Crespo G., D'Amato M., et al. Intravenous silibinin monotherapy shows significant antiviral activity in HCV-infected patients in the peri-transplantation period. Journal of Hepatology. 2013;58(3):415–420. doi: 10.1016/j.jhep.2012.09.034. PubMed DOI

Beinhardt S., Rasoul-Rockenschaub S., Scherzer T. M., Ferenci P. Silibinin monotherapy prevents graft infection after orthotopic liver transplantation in a patient with chronic hepatitis C. Journal of Hepatology. 2011;54(3):591–592. doi: 10.1016/j.jhep.2010.09.009. PubMed DOI

Neumann U. P., Biermer M., Eurich D., Neuhaus P., Berg T. Successful prevention of hepatitis C virus (HCV) liver graft reinfection by silibinin mono-therapy. Journal of Hepatology. 2010;52(6):951–952. doi: 10.1016/j.jhep.2010.02.002. PubMed DOI

de Avelar C. R., Pereira E. M., de Farias Costa P. R., de Jesus R. P., de Oliveira L. P. M. Effect of silymarin on biochemical indicators in patients with liver disease: systematic review with meta-analysis. World Journal of Gastroenterology. 2017;23(27):5004–5017. doi: 10.3748/wjg.v23.i27.5004. PubMed DOI PMC

Simanek V., Kren V., Ulrichova J., Vicar J., Cvak L. Silymarin: what is in the name…? An appeal for a change of editorial policy. Hepatology. 2000;32(2):442–444. doi: 10.1053/jhep.2000.9770. PubMed DOI

Chambers C. S., Holeckova V., Petraskova L., et al. The silymarin composition… and why does it matter??? Food Research International. 2017;100, Part 3:339–353. doi: 10.1016/j.foodres.2017.07.017. PubMed DOI

Kim N. C., Graf T. N., Sparacino C. M., Wani M. C., Wall M. E. Complete isolation and characterization of silybins and isosilybins from milk thistle (Silybum marianum) Organic & Biomolecular Chemistry. 2003;1(10):1684–1689. doi: 10.1039/b300099k. PubMed DOI

Kren V., Walterova D. Silybin and silymarin - new effects and applications. Biomed Papers. 2005;149(1):29–41. doi: 10.5507/bp.2005.002. PubMed DOI

Pyszkova M., Biler M., Biedermann D., et al. Flavonolignan 2,3-dehydroderivatives: preparation, antiradical and cytoprotective activity. Free Radical Biology and Medicine. 2016;90:114–125. doi: 10.1016/j.freeradbiomed.2015.11.014. PubMed DOI

Karas D., Gazak R., Valentova K., et al. Effects of 2,3-dehydrosilybin and its galloyl ester and methyl ether derivatives on human umbilical vein endothelial cells. Journal of Natural Products. 2016;79(4):812–820. doi: 10.1021/acs.jnatprod.5b00905. PubMed DOI

Biedermann D., Buchta M., Holeckova V., et al. Silychristin: skeletal alterations and biological activities. Journal of Natural Products. 2016;79(12):3086–3092. doi: 10.1021/acs.jnatprod.6b00750. PubMed DOI

Filippopoulou K., Papaevgeniou N., Lefaki M., et al. 2,3-Dehydrosilybin A/B as a pro-longevity and anti-aggregation compound. Free Radical Biology and Medicine. 2017;103:256–267. doi: 10.1016/j.freeradbiomed.2016.12.042. PubMed DOI

Gazak R., Marhol P., Purchartova K., et al. Large-scale separation of silybin diastereoisomers using lipases. Process Biochemistry. 2010;45(10):1657–1663. doi: 10.1016/j.procbio.2010.06.019. DOI

Gazak R., Trouillas P., Biedermann D., et al. Base-catalyzed oxidation of silybin and isosilybin into 2,3-dehydroderivatives. Tetrahedron Letters. 2013;54(4):315–317. doi: 10.1016/j.tetlet.2012.11.049. DOI

Gerstorferova D., Fliedrova B., Halada P., Marhol P., Kren V., Weignerova L. Recombinant α-L-rhamnosidase from Aspergillus terreus in selective trimming of rutin. Process Biochemistry. 2012;47(5):828–835. doi: 10.1016/j.procbio.2012.02.014. DOI

Zelenka J., Lenicek M., Muchova L., et al. Highly sensitive method for quantitative determination of bilirubin in biological fluids and tissues. Journal of Chromatography B. 2008;867(1):37–42. doi: 10.1016/j.jchromb.2008.03.005. PubMed DOI

Zelenka J., Muchova L., Zelenkova M., et al. Intracellular accumulation of bilirubin as a defense mechanism against increased oxidative stress. Biochimie. 2012;94(8):1821–1827. doi: 10.1016/j.biochi.2012.04.026. PubMed DOI

Vreman H. J., Stevenson D. K. Heme oxygenase activity as measured by carbon monoxide production. Analytical Biochemistry. 1988;168(1):31–38. doi: 10.1016/0003-2697(88)90006-1. PubMed DOI

Wills E. D. Mechanisms of lipid peroxide formation in animal tissues. The Biochemical Journal. 1966;99(3):667–676. doi: 10.1042/bj0990667. PubMed DOI PMC

Zhang D., Chando T. J., Everett D. W., Patten C. J., Dehal S. S., Humphreys W. G. In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metabolism and Disposition. 2005;33(11):1729–1739. doi: 10.1124/dmd.105.005447. PubMed DOI

Gazzin S., Masutti F., Vitek L., Tiribelli C. The molecular basis of jaundice: an old symptom revisited. Liver International. 2017;37(8):1094–1102. doi: 10.1111/liv.13351. PubMed DOI

Novotny L., Vitek L. Inverse relationship between serum bilirubin and atherosclerosis in men: a meta-analysis of published studies. Experimental Biology and Medicine. 2003;228(5):568–571. doi: 10.1177/15353702-0322805-29. PubMed DOI

Jiraskova A., Novotny J., Novotny L., et al. Association of serum bilirubin and promoter variations in HMOX1 and UGT1A1 genes with sporadic colorectal cancer. International Journal of Cancer. 2012;131(7):1549–1555. doi: 10.1002/ijc.27412. PubMed DOI

Lenicek M., Duricova D., Hradsky O., et al. The relationship between serum bilirubin and Crohn’s disease. Inflammatory Bowel Diseases. 2014;20(3):481–487. doi: 10.1097/01.MIB.0000440817.84251.98. PubMed DOI

Vitek L., Jirsa M., Brodanova M., et al. Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels. Atherosclerosis. 2002;160(2):449–456. doi: 10.1016/S0021-9150(01)00601-3. PubMed DOI

Sridar C., Goosen T. C., Kent U. M., Williams J. A., Hollenberg P. F. Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases. Drug Metabolism and Disposition. 2004;32(6):587–594. doi: 10.1124/dmd.32.6.587. PubMed DOI

Hoh C., Boocock D., Marczylo T., et al. Pilot study of oral silibinin, a putative chemopreventive agent, in colorectal cancer patients: silibinin levels in plasma, colorectum, and liver and their pharmacodynamic consequences. Clinical Cancer Research. 2006;12(9):2944–2950. doi: 10.1158/1078-0432.CCR-05-2724. PubMed DOI

Barzaghi N., Crema F., Gatti G., Pifferi G., Perucca E. Pharmacokinetic studies on IdB 1016, a silybin-phosphatidylcholine complex, in healthy human subjects. European Journal of Drug Metabolism and Pharmacokinetics. 1990;15(4):333–338. doi: 10.1007/BF03190223. PubMed DOI

Wen Z., Dumas T. E., Schrieber S. J., Hawke R. L., Fried M. W., Smith P. C. Pharmacokinetics and metabolic profile of free, conjugated, and total silymarin flavonolignans in human plasma after oral administration of milk thistle extract. Drug Metabolism and Disposition. 2008;36(1):65–72. doi: 10.1124/dmd.107.017566. PubMed DOI

Gufford B. T., Chen G., Lazarus P., Graf T. N., Oberlies N. H., Paine M. F. Identification of diet-derived constituents as potent inhibitors of intestinal glucuronidation. Drug Metabolism and Disposition. 2014;42(10):1675–1683. doi: 10.1124/dmd.114.059451. PubMed DOI PMC

Wlcek K., Koller F., Ferenci P., Stieger B. Hepatocellular organic anion-transporting polypeptides (OATPs) and multidrug resistance-associated protein 2 (MRP2) are inhibited by silibinin. Drug Metabolism and Disposition. 2013;41(8):1522–1528. doi: 10.1124/dmd.113.051037. PubMed DOI

Forman H. J., Davies K. J., Ursini F. How do nutritional antioxidants really work: nucleophilic tone and para-hormesis versus free radical scavenging in vivo . Free Radical Biology and Medicine. 2014;66:24–35. doi: 10.1016/j.freeradbiomed.2013.05.045. PubMed DOI PMC

Role of Natural Compounds Modulating Heme Catabolic Pathway in Gut, Liver, Cardiovascular, and Brain Diseases

The Effect of Mycotoxins and Silymarin on Liver Lipidome of Mice with Non-Alcoholic Fatty Liver Disease

Chirality Matters: Biological Activity of Optically Pure Silybin and Its Congeners

Metabolism of 2,3-Dehydrosilybin A and 2,3-Dehydrosilybin B: A Study with Human Hepatocytes and Recombinant UDP-Glucuronosyltransferases and Sulfotransferases

Complex Evaluation of Antioxidant Capacity of Milk Thistle Dietary Supplements

Poor chemical and microbiological quality of the commercial milk thistle-based dietary supplements may account for their reported unsatisfactory and non-reproducible clinical outcomes